APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acquired Immunodeficiency Syndrome

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Acquired Immunodeficiency Syndrome Market Analysis and Forecast 2026-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchAcquired Immunodeficiency Syndrome Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Acquired Immunodeficiency Syndrome Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Acquired Immunodeficiency Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acquired Immunodeficiency Syndrome Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Acquired Immunodeficiency Syndrome Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Acquired Immunodeficiency Syndrome market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Acquired Immunodeficiency Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Acquired Immunodeficiency Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Acquired Immunodeficiency Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Acquired Immunodeficiency Syndrome is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Acquired Immunodeficiency Syndrome include Takeda, Sanofi, Novartis, Pfizer, Amgen, Merck KGaA, Daiichi Sankyo Company, Biogen and AstraZeneca Eli Lilly and Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Acquired Immunodeficiency Syndrome, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Acquired Immunodeficiency Syndrome, also provides the revenue of main regions and countries. Of the upcoming market potential for Acquired Immunodeficiency Syndrome, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acquired Immunodeficiency Syndrome revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Acquired Immunodeficiency Syndrome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Acquired Immunodeficiency Syndrome revenue, projected growth trends, production technology, application and end-user industry.

Acquired Immunodeficiency Syndrome Segment by Company

Takeda

Sanofi

Novartis

Pfizer

Amgen

Merck KGaA

Daiichi Sankyo Company

Biogen

AstraZeneca Eli Lilly and Company

Actelion

Acquired Immunodeficiency Syndrome Segment by Type

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Acquired Immunodeficiency Syndrome Segment by Application

Hospital Pharmacy

Retail Pharmacy

Others

Acquired Immunodeficiency Syndrome Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acquired Immunodeficiency Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acquired Immunodeficiency Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acquired Immunodeficiency Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Acquired Immunodeficiency Syndrome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Acquired Immunodeficiency Syndrome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acquired Immunodeficiency Syndrome revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Major Player Table 3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Major Player Table 4. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacy Major Player Table 6. Retail Pharmacy Major Player Table 7. Others Major Player Table 8. Acquired Immunodeficiency Syndrome Industry Trends Table 9. Acquired Immunodeficiency Syndrome Industry Drivers Table 10. Acquired Immunodeficiency Syndrome Industry Opportunities and Challenges Table 11. Acquired Immunodeficiency Syndrome Industry Restraints Table 12. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Acquired Immunodeficiency Syndrome Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Acquired Immunodeficiency Syndrome Market Share by Region (2021-2026) Table 15. Global Acquired Immunodeficiency Syndrome Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Acquired Immunodeficiency Syndrome Market Share by Region (2027-2032) Table 17. Global Acquired Immunodeficiency Syndrome Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Players (2021-2026) Table 19. Global Acquired Immunodeficiency Syndrome Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Acquired Immunodeficiency Syndrome Key Players Headquarters & Area Served Table 21. Global Acquired Immunodeficiency Syndrome Players, Product Type & Application Table 22. Global Acquired Immunodeficiency Syndrome Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Acquired Immunodeficiency Syndrome by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Acquired Immunodeficiency Syndrome Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2021-2026) Table 29. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2027-2032) Table 30. Global Acquired Immunodeficiency Syndrome Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Application (2021-2026) Table 34. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Application (2027-2032) Table 35. Takeda Company Information Table 36. Takeda Business Overview Table 37. Takeda Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Takeda Acquired Immunodeficiency Syndrome Product Portfolio Table 39. Takeda Recent Development Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Acquired Immunodeficiency Syndrome Product Portfolio Table 44. Sanofi Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Acquired Immunodeficiency Syndrome Product Portfolio Table 49. Novartis Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pfizer Acquired Immunodeficiency Syndrome Product Portfolio Table 54. Pfizer Recent Development Table 55. Amgen Company Information Table 56. Amgen Business Overview Table 57. Amgen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Amgen Acquired Immunodeficiency Syndrome Product Portfolio Table 59. Amgen Recent Development Table 60. Merck KGaA Company Information Table 61. Merck KGaA Business Overview Table 62. Merck KGaA Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Merck KGaA Acquired Immunodeficiency Syndrome Product Portfolio Table 64. Merck KGaA Recent Development Table 65. Daiichi Sankyo Company Company Information Table 66. Daiichi Sankyo Company Business Overview Table 67. Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product Portfolio Table 69. Daiichi Sankyo Company Recent Development Table 70. Biogen Company Information Table 71. Biogen Business Overview Table 72. Biogen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Biogen Acquired Immunodeficiency Syndrome Product Portfolio Table 74. Biogen Recent Development Table 75. AstraZeneca Eli Lilly and Company Company Information Table 76. AstraZeneca Eli Lilly and Company Business Overview Table 77. AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product Portfolio Table 79. AstraZeneca Eli Lilly and Company Recent Development Table 80. Actelion Company Information Table 81. Actelion Business Overview Table 82. Actelion Acquired Immunodeficiency Syndrome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Actelion Acquired Immunodeficiency Syndrome Product Portfolio Table 84. Actelion Recent Development Table 85. North America Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Acquired Immunodeficiency Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Acquired Immunodeficiency Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 99. China Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 100. China Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 101. China Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 102. China Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Acquired Immunodeficiency Syndrome Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Acquired Immunodeficiency Syndrome Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Acquired Immunodeficiency Syndrome Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Acquired Immunodeficiency Syndrome Image Figure 2. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acquired Immunodeficiency Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Image Figure 5. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Image Figure 6. Global Acquired Immunodeficiency Syndrome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Acquired Immunodeficiency Syndrome Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacy Image Figure 9. Retail Pharmacy Image Figure 10. Others Image Figure 11. Global Acquired Immunodeficiency Syndrome Market Size (US$ Million) & (2021-2032) Figure 12. Global Acquired Immunodeficiency Syndrome Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Acquired Immunodeficiency Syndrome Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Acquired Immunodeficiency Syndrome Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Acquired Immunodeficiency Syndrome Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Acquired Immunodeficiency Syndrome Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2021-2032) Figure 19. Global Acquired Immunodeficiency Syndrome Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Acquired Immunodeficiency Syndrome Revenue Market Share by Application (2021-2032) Figure 22. North America Acquired Immunodeficiency Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032) Figure 24. North America Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032) Figure 25. North America Acquired Immunodeficiency Syndrome Revenue Share by Country (2021-2032) Figure 26. United States Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Acquired Immunodeficiency Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032) Figure 31. Europe Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032) Figure 32. Europe Acquired Immunodeficiency Syndrome Revenue Share by Country (2021-2032) Figure 33. Germany Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Acquired Immunodeficiency Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032) Figure 43. China Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032) Figure 44. Asia Acquired Immunodeficiency Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032) Figure 46. Asia Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032) Figure 47. Asia Acquired Immunodeficiency Syndrome Revenue Share by Region (2021-2032) Figure 48. Japan Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Acquired Immunodeficiency Syndrome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032) Figure 56. SAMEA Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032) Figure 57. SAMEA Acquired Immunodeficiency Syndrome Revenue Share by Country (2021-2032) Figure 58. Brazil Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Acquired Immunodeficiency Syndrome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Pfizer
  • Amgen
  • Merck KGaA
  • Daiichi Sankyo Company
  • Biogen
  • AstraZeneca Eli Lilly and Company
  • Actelion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Acquired Immunodeficiency Syndrome Market by Type
  3. 1.2.1 Global Acquired Immunodeficiency Syndrome Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  5. 1.2.3 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  6. 1.3 Acquired Immunodeficiency Syndrome Market by Application
  7. 1.3.1 Global Acquired Immunodeficiency Syndrome Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacy
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Acquired Immunodeficiency Syndrome Market Dynamics
  1. 2.1 Acquired Immunodeficiency Syndrome Industry Trends
  2. 2.2 Acquired Immunodeficiency Syndrome Industry Drivers
  3. 2.3 Acquired Immunodeficiency Syndrome Industry Opportunities and Challenges
  4. 2.4 Acquired Immunodeficiency Syndrome Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Acquired Immunodeficiency Syndrome Market Perspective (2021-2032)
  2. 3.2 Global Acquired Immunodeficiency Syndrome Growth Trends by Region
  3. 3.2.1 Global Acquired Immunodeficiency Syndrome Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Acquired Immunodeficiency Syndrome Market Size by Region (2021-2026)
  5. 3.2.3 Global Acquired Immunodeficiency Syndrome Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Acquired Immunodeficiency Syndrome Revenue by Players
  2. 4.1.1 Global Acquired Immunodeficiency Syndrome Revenue by Players (2021-2026)
  3. 4.1.2 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Acquired Immunodeficiency Syndrome Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Acquired Immunodeficiency Syndrome Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Acquired Immunodeficiency Syndrome Key Players Headquarters & Area Served
  7. 4.4 Global Acquired Immunodeficiency Syndrome Players, Product Type & Application
  8. 4.5 Global Acquired Immunodeficiency Syndrome Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Acquired Immunodeficiency Syndrome Market CR5 and HHI
  11. 4.6.3 2025 Acquired Immunodeficiency Syndrome Tier 1, Tier 2, and Tier 3
5 Acquired Immunodeficiency Syndrome Market Size by Type
  1. 5.1 Global Acquired Immunodeficiency Syndrome Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 5.3 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Type (2021-2032)
6 Acquired Immunodeficiency Syndrome Market Size by Application
  1. 6.1 Global Acquired Immunodeficiency Syndrome Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  3. 6.3 Global Acquired Immunodeficiency Syndrome Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Acquired Immunodeficiency Syndrome Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Acquired Immunodeficiency Syndrome Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Acquired Immunodeficiency Syndrome Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Acquired Immunodeficiency Syndrome Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 Amgen
  26. 7.5.1 Amgen Company Information
  27. 7.5.2 Amgen Business Overview
  28. 7.5.3 Amgen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Acquired Immunodeficiency Syndrome Product Portfolio
  30. 7.5.5 Amgen Recent Developments
  31. 7.6 Merck KGaA
  32. 7.6.1 Merck KGaA Company Information
  33. 7.6.2 Merck KGaA Business Overview
  34. 7.6.3 Merck KGaA Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck KGaA Acquired Immunodeficiency Syndrome Product Portfolio
  36. 7.6.5 Merck KGaA Recent Developments
  37. 7.7 Daiichi Sankyo Company
  38. 7.7.1 Daiichi Sankyo Company Company Information
  39. 7.7.2 Daiichi Sankyo Company Business Overview
  40. 7.7.3 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Daiichi Sankyo Company Acquired Immunodeficiency Syndrome Product Portfolio
  42. 7.7.5 Daiichi Sankyo Company Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Acquired Immunodeficiency Syndrome Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 AstraZeneca Eli Lilly and Company
  50. 7.9.1 AstraZeneca Eli Lilly and Company Company Information
  51. 7.9.2 AstraZeneca Eli Lilly and Company Business Overview
  52. 7.9.3 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Eli Lilly and Company Acquired Immunodeficiency Syndrome Product Portfolio
  54. 7.9.5 AstraZeneca Eli Lilly and Company Recent Developments
  55. 7.10 Actelion
  56. 7.10.1 Actelion Company Information
  57. 7.10.2 Actelion Business Overview
  58. 7.10.3 Actelion Acquired Immunodeficiency Syndrome Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Actelion Acquired Immunodeficiency Syndrome Product Portfolio
  60. 7.10.5 Actelion Recent Developments
8 North America
  1. 8.1 North America Acquired Immunodeficiency Syndrome Revenue (2021-2032)
  2. 8.2 North America Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 8.2.1 North America Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026)
  4. 8.2.2 North America Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032)
  5. 8.3 North America Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032)
  6. 8.4 North America Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  7. 8.4.1 North America Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026)
  8. 8.4.2 North America Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032)
  9. 8.5 North America Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032)
  10. 8.6 North America Acquired Immunodeficiency Syndrome Revenue by Country
  11. 8.6.1 North America Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026)
  13. 8.6.3 North America Acquired Immunodeficiency Syndrome Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Acquired Immunodeficiency Syndrome Revenue (2021-2032)
  2. 9.2 Europe Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 9.2.1 Europe Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026)
  4. 9.2.2 Europe Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032)
  5. 9.3 Europe Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032)
  6. 9.4 Europe Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  7. 9.4.1 Europe Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026)
  8. 9.4.2 Europe Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032)
  9. 9.5 Europe Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032)
  10. 9.6 Europe Acquired Immunodeficiency Syndrome Revenue by Country
  11. 9.6.1 Europe Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026)
  13. 9.6.3 Europe Acquired Immunodeficiency Syndrome Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Acquired Immunodeficiency Syndrome Revenue (2021-2032)
  2. 10.2 China Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 10.2.1 China Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026)
  4. 10.2.2 China Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032)
  5. 10.3 China Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032)
  6. 10.4 China Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  7. 10.4.1 China Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026)
  8. 10.4.2 China Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032)
  9. 10.5 China Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Acquired Immunodeficiency Syndrome Revenue (2021-2032)
  2. 11.2 Asia Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 11.2.1 Asia Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026)
  4. 11.2.2 Asia Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032)
  5. 11.3 Asia Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032)
  6. 11.4 Asia Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  7. 11.4.1 Asia Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026)
  8. 11.4.2 Asia Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032)
  9. 11.5 Asia Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032)
  10. 11.6 Asia Acquired Immunodeficiency Syndrome Revenue by Country
  11. 11.6.1 Asia Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026)
  13. 11.6.3 Asia Acquired Immunodeficiency Syndrome Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Acquired Immunodeficiency Syndrome Revenue (2021-2032)
  2. 12.2 SAMEA Acquired Immunodeficiency Syndrome Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Acquired Immunodeficiency Syndrome Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Acquired Immunodeficiency Syndrome Revenue by Type (2027-2032)
  5. 12.3 SAMEA Acquired Immunodeficiency Syndrome Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Acquired Immunodeficiency Syndrome Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Acquired Immunodeficiency Syndrome Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Acquired Immunodeficiency Syndrome Revenue by Application (2027-2032)
  9. 12.5 SAMEA Acquired Immunodeficiency Syndrome Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Acquired Immunodeficiency Syndrome Revenue by Country
  11. 12.6.1 SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Acquired Immunodeficiency Syndrome Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst